IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: William J. Watkins Art Unit: 1624

Title : KINASE INHIBITOR PHOSPHONATE CONJUGATES

RESPONSE TO SUPPLEMENTAL RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

This is in response to the Supplemental Restriction Requirement mailed on March 25, 2008. The Examiner requested election of one of the following groups:

- I. Claims 1, 2, 4-55, 57, 58 and 71 which are drawn to compounds of formula (I), wherein Ll and L2 are carbon and form a substituted pyrrolo[2,3-d]pyrimidine, compositions thereof and a process of making said compositions.
- II. Claims 1, 2, 4-55, 57, 58 and 71 which are drawn to compounds of formula (I), wherein Ll is nitrogen and L2 is carbon and form a substituted purine, compositions thereof and a process of making said compositions.
- III. Claims 1-3, 5-55, 57, 58 and 71 which are drawn to compounds of formula (I), wherein Ll is carbon and L2 is nitrogen and form a substituted pyrazolo[3,4-d]pyrimidine,

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is transmitted by facsimile, by electronic transmission, or is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 25, 2008 Date of Deposit	
Date of Deposit	
Nursue Helulion	
Signature	
Michelle McCullough	_
Typed or Printed Name of Person Signing Certificate	

Applicant: William J. Watkins Attorney's Docket No.: 01692.315US2

Serial No.: 10/583,683 Filed: April 11, 2007

Page : 2 of 4

compositions thereof and a process of making said compositions.

IV. Claims 1, 57, 58 and 71 which are drawn to compounds of formula (I), wherein Ll is nitrogen and L2 is nitrogen and form a substituted [1,2,3]triazolo[4,5-d]pyrimidine, compositions thereof and a process of making said compositions.

- V. Claims 59-64 which are drawn to a method of inhibiting a kinase with compounds of formula (I), wherein Ll is nitrogen and L2 is nitrogen and form a substituted pyrrolo[2,3-d]pyrimidine.
- VI. Claims 59-64 which are drawn to a method of inhibiting a kinase with compounds of formula (I), wherein L1 and L2 are carbon and form a substituted purine.
- VII. Claims 59-64 which are drawn to a method of inhibiting a kinase with compounds of formula (I), wherein L1 is nitrogen and L2 is carbon and form a substituted pyrazolo[3,4-d]pyrimidine.
- VIII. Claims 59-64 which are drawn to a method of inhibiting a kinase with compounds of formula (I), wherein L1 is nitrogen and L2 is carbon and form a substituted [1,2,3]triazolo[4,5-d]pyrimidine.
- IX. Claim 65 which is drawn to a method of treating cancer with compounds of formula (I), wherein L1 and L2 are carbon and form a substituted pyrrolo[2,3-d]pyrimidine.
- X. Claim 65 which is drawn to a method of treating cancer with compounds of formula (I), wherein L1 is nitrogen and L2 is carbon and form a substituted purine.
- XI. Claim 65 which is drawn to a method of treating cancer with compounds of formula (I), wherein Ll is nitrogen and L2 is nitrogen and form a substituted pyrazolo[3,4-d]pyrimidine.